Carnitine deficiency has been demonstrated in diabetic hearts, and it is also well known that L-carnitine administration has a beneficial effect on cardiac function. Carnitine treatment would be expected to reduce the accumulation of long-chain acylcarnitine. However, many reports have shown that myocardial long-chain acylcarnitine levels were increased following treatment with L-carnitine in whole-heart studies. Since acylcarnitine exists in both the mitochondrial and cytosolic compartments, it is difficult to investigate changes in subcellular distribution by studying whole-heart preparations. The present study investigated the myocardial subcellular distribution of carnitine and its acyl derivatives in diabetic rats with or without L-carnitine treatment. Approximately 90% of total cellular carnitine was located in the cytosol in the diabetic hearts. Both mitochondrial and cytosolic levels of free carnitine and short-chain acylcarnitine were significantly decreased in the diabetic heart. However, the mitochondrial level of long-chain acylcarnitine was significantly increased. Lcarnitine treatment reduced the mitochondrial level of long-chain acylcarnitine, but the cytosolic level of long-chain acylcarnitine was significantly increased. These results show that L-carnitine treatment prevents the accumulation of long-chain acylcarnitine in the mitochondrial space and then reduces the detergent effect of long-chain acylcarnitine on the mitochondrial membrane. We suggest that it is a possible mechanism of the beneficial effect of L-carnitine treatment on the diabetic heart. (Jpn Heart J 34: 763-772, 1993) Key Words: Free carnitine Long-chain acylcarnitine Cellular distribution Mitochondria Diabetic heart L-carnitine treatment HRONIC diabetes mellitus is known to result in myocardial abnormalities.
mitochondrial distribution of long-chain acylcarnitine in the diabetic heart. However, there are no reports of investigation of the changes in mitochondrial levels of long-chain acylcarnitine in the diabetic heart with L-carnitine treatment.
The purpose of the present study is to assess the effect of L-carnitine on the cellular distribution of carnitine and its acyl derivatives in the diabetic rat heart.
MATERIALS AND METHODS

Animals:
Thirty male Wistar rats aged 8 weeks were used. Diabetes was induced by a single injection of streptozocin (STZ 40mg/kg) dissolved in citrate Fig.1 elevated in the diabetic rats compared with the controls (p<0.01), while there was no significant difference between the diabetic rats with and without L-carnitine treatment.
Isolation of the cytosolic and mitochondrial fractions: Mitochondrial protein ranged from 40 to 60mg of protein/g wet heart muscle in the diabetic rats and the mitochondrial recovery rate was 80%. Lactate dehydrogenase activity (cytoplasmic marker enzyme) was not detected in the mitochondria) fraction and citrate synthase (a mitochondria) marker enzyme) was not extracted from the mitochondria by washing in the isolation buffer. In addition, citrate synthase was not detected in the cytosol fraction. Changes in carnitine and its acyl derivatives in diabetic rat hearts: Table II shows the concentrations of carnitine and its acyl groups in whole-heart homogenates. The concentrations of free carnitine, short-chain acylcarnitine, and total carnitine were significantly decreased in the diabetic rat hearts compared with the control hearts (all p<0.01). On the other hand, the concentration of long-chain acylcarnitine was significantly increased in the diabetic hearts (p<0.01). Table III shows the concentrations of carnitine and its acyl derivatives in the cytosolic and mitochondrial fractions of the three groups. In the control rats, approximately 90% of cellular free carnitine, 89% of cellular short-chain acylcarnitinc, and 85% of cellular long-chain acylcarnitine were located within the cytosolic compartment. In the untreated diabetic rats, the concentrations of free carnitine and short-chain acylcarnitine in the cytosol and the mitochondria were significantly reduced (both p<0.01). On the other hand, the long-chain acylcarnitine concentration was significantly increased in both the cytosol and the mitochondria (p<0.05 and p<0.01, respectively). The percentage increase in long-chain acylcarnitine was greater in the mitochondrial compartment than in the cytosol (177% vs 80%). Effects of L-carnitine on the subcellular distribution of carnitine and its acyl derivatives: Table II shows the concentrations of carnitine and its acyl groups in whole-heart homogenates. Administration of L-carnitine significantly increased free carnitine, short-chain acylcarnitine and total carnitine concentrations, respectively (all p<0.01). However, the level of long-chain acylcarnitine in the whole-heart homogenate from diabetic rats showed a greater increase following L-carnitine administration (p<0.05). Table III shows the effect of L-carnitine administration on the subcellular distribution of carnitine and its acyl derivatives in diabetic rats. L-carnitine treatment produced differential changes in the carnitine distribution of the cytosolic and mitochondrial compartments. The levels of free carnitine and short-chain acylcarnitine were significantly increased in both the cytosolic and mitochondrial compartments. However, the mitochondrial level of long-chain acylcarnitine was significantly decreased by treatment with L-carnitine, and fell to the same level as Jpn. Heart J. November, 1993 that in the control rats. In contrast, the cytosolic level of long-chain acylcarnitine was significantly increased by treatment with L-carnitine.
DISCUSSION
The subcellular distribution of carnitine, CoA, and their acyl derivatives in normal and ischemic rat hearts was first studied by Idell-Wenger et al.) Lopaschuk et all20) examined sarcoplasmic reticulum levels of long-chain acylcarnitine in the diabetic heart. Cardiac sarcoplasmic reticulum levels of longchain acylcarnitine were significantly elevated, and insulin and D, L-carnitine treatment can lower sarcoplasmic reticulum levels of long-chain acylcarnitine. However, the subcellular distribution (cytosol and mitochondria) of carnitine and CoA has not yet been investigated in the diabetic heart.
Although it may have been preferable to examine the distribution of carnitine, CoA, and their acyl derivatives, there are some problems regarding the loss and redistribution of metabolites during the preparation of mitochondrial and cytosolic fractions. We have already studied the subcellular distribution of carnitine and its acyl derivatives in normal and ischemic canine hearts.22) Lactate dehydrogenase activity was not detected in the mitochondria) fraction, and the cytosolic fraction contained only about 5% cell membrane contamination. In addition, exogenous [14C]-carnitine and [14C]-palmitoyl carnitine were completely recovered in the post-supernatant mitochondrial fraction and the residual mitochondrial fraction, respectively, whereas neither form of labeled carnitine was detected in the mitochondrial fraction itself. These results indicate that metabolism of carnitine and its acyl derivatives did not occur during preparation of the mitochondrial and cytosolic fractions, and that it is not necessary to correct the values obtained for carnitine. 22) Approximately 90% of total cellular carnitine was located in the cytosolic compartment in the diabetic rat hearts. Marked changes in the cellular distribution of carnitine and long-chain acylcarnitine occurred in diabetic hearts, and these changes were especially prominent in the mitochondrial compartment. A large percentage of the total intracellular water is in the cytosolic compartment, and only 19% of it is in the mitochondria, the sarcoplasmic reticulum and the other subcellular compartments.26) Therefore, even a small change in long-chain acylcarnitine level in the mitochondrial compartment could lead to a relatively large effect on long-chain acylcarnitine. Long-chain acylcarnitine has a detergent action and inhibits the activity of enzymes like Na+, K+-ATPase.12-15) IdellWenger et al21) have also suggested that long-chain acylcarnitine may have an adverse detergent effect on the mitochondrial membrane in ischemic hearts. Therefore, it is possible that the detergent effect of long-chain acylcarnitine on the mitochondrial membrane may be detrimental to the function of mitochondria in diabetic hearts.
L-carnitine treatment would be expected to reduce the accumulation of long-chain acylcarnitine in diabetic hearts. However, myocardial long-chain acylcarnitine levels (whole-heart homogenates) were significantly increased by treatment with L-carnitine. On the other hand, the mitochondrial level of longchain acylcarnitine was significantly decreased by L-carnitine treatment. These results confirm that L-carnitine treatment reduces the accumulation of longchain acylcarnitine in the mitochondrial compartment and prevents the detrimental detergent effect on the mitochondrial membrane. In addition, if we had analyzed whole-heart preparations, we could not have detected any reduction of long-chain acylcarnitine in the mitochondrial compartment.
The reduction of long-chain acylcarnitine in the mitochondria may allow better utilization of fatty acids. In support of this hypothesis, Fritz et al have shown that fatty acid oxidation is stimulated by the addition of carnitine to isolated heart mitochondria.27) However, the addition of carnitine to intact tissue does not always enhance fatty acid uptake and oxidation.28) The diabetic heart depends on fatty acid for its production of energy. Therefore, better utilization of fatty acids in mitochondria could increase ATP levels and improve myocardial performance. The mechanism by which carnitine treatment can lower mitochondrial levels of long-chain acylcarnitine is as yet unknown. It is possible that carnitine may lower the activity of intracellular long-chain acylcarnitine translocase enzyme in the mitochondrial membrane.
In conclusion, L-carnitine treatment reduced the accumulation of longchain acylcarnitine in the mitochondrial compartment in diabetic rat hearts. This study indicates that the reduction in mitochondrial levels of long-chain acylcarnitine suppresses the detergent effect of long-chain acylcarnitine on the mitochondrial membrane, and that this mechanism may be related to the beneficial effect of L-carnitine on the diabetic heart.
